Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo.

导出原文传递

翻译打印收藏纠错

作者： K,Isa ^[1] ; K,Oka ^[1] ; N,Beauchamp ^[2] ; M,Sato ^[1] ; K,Wada ^[1] ; K,Ohtani ^[3] ; S,Nakanishi ^[4] ; E,McCartney ^[5] ; M,Tanaka ^[1] ; T,Shimizu ^[6] ; S,Kamiya ^[7] ; C,Kruger ^[2] ; M,Takahashi ^[8]

作者单位： Miyarisan Pharmaceutical Co., Ltd, Tokyo, Japan. ^[1] Spherix Consulting, Rockville, MD, USA. ^[2] Department of Bacteriology, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan. ^[3] Miyarisan Pharmaceutical Co., Ltd, Tokyo, Japan Deceased. ^[4] Pen & Tec Consulting, Barcelona, Spain. ^[5] Department of Bacteriology, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan Deceased. ^[6] Department of Infectious Diseases, Kyorin University School of Medicine, Tokyo, Japan. ^[7] Miyarisan Pharmaceutical Co., Ltd, Tokyo, Japan Department of Infectious Diseases, Kyorin University School of Medicine, Tokyo, Japan motomichi.takahashi@miyarisan.com. ^[8]

关键词 CBM 588? probiotic Clostridium butyricum MIYAIRI 588?Clostridium toxins antibiotic sensitivity reproductive and developmental toxicity teratogenicity